entity

ALPHA_SYN

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ALPHA_SYN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1Connections
24Hypotheses
0Analyses
1Outgoing
0Incoming
0Experiments
0Debates

No AI portrait yet

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Enteric Neurons with Alpha-Synuclein Pathology

cell · 659 words

Outgoing (1)

TargetRelationTypeStr
C3activatesprotein0.56

Incoming (0)

SourceRelationTypeStr
No incoming edges

Targeting Hypotheses (24)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S 0.822 neurodegeneration What are the mechanisms by which gut mic
GBA1/GCase restoration to reduce alpha-synuclein pathology i 0.760 neurodegeneration Test
LAMP2A-Mediated Autophagy Enhancement Blocks Alpha-Synuclein 0.745 neurodegeneration Test
Pharmacologic activation of GBA1 to reduce alpha-synuclein b 0.720 neurodegeneration Test
A downstream LRRK2-Rab10-JIP4 lysosomal stress loop promotes 0.680 neurodegeneration Do pathogenic LRRK2 mutations amplify vo
m6A Hypermethylation of SNCA mRNA Stabilises Alpha-Synuclein 0.662 parkinson m6A RNA Modification and Alpha-Synuclein
Alpha-synuclein phosphorylation-dominated LLPS hijacks synap 0.657 parkinsons -
Physiological SCFAs may reduce alpha-synuclein burden primar 0.650 neurodegeneration Do physiological concentrations of SCFAs
LRRK2 Haploinsufficiency Traps Microglia in Senescence-Like 0.650 parkinsons -
m6A-dependent control of alpha-synuclein transcript fate and 0.626 neurodegeneration m6A RNA Modification and Alpha-Synuclein
H7: Enteric Nervous System Alpha-Synuclein Propagation Block 0.620 neurodegeneration How does engineered C. butyricum cross t
Cell-state stratification is required to resolve m6A RNA Mod 0.612 neurodegeneration m6A RNA Modification and Alpha-Synuclein
Perturbation-first validation should precede therapeutic cla 0.608 neurodegeneration m6A RNA Modification and Alpha-Synuclein
CSF ApoE- and clusterin-rich lipoprotein particles stabilize 0.606 neurodegeneration Which specific CSF molecular components
Ganglioside-rich extracellular vesicles preserve alpha-synuc 0.582 neurodegeneration Which specific CSF molecular components
Neuronal Subtype-Specific Alpha-Synuclein Expression Normali 0.571 neurodegeneration De Novo Binder Design Targeting Alpha-Sy
Direct neuronal HDAC inhibition is unlikely to mediate thera 0.560 neurodegeneration Do physiological concentrations of SCFAs
Physiological SCFAs may worsen alpha-synuclein pathology thr 0.550 neurodegeneration Do physiological concentrations of SCFAs
Glucosylceramide accumulation nucleates alpha-synuclein aggr 0.525 parkinsons GBA-Synuclein Loop Therapeutics for PD
Sulfated glycans and metal-binding CSF proteins brace alpha- 0.489 neurodegeneration Which specific CSF molecular components
Propionate may outperform acetate or butyrate at physiologic 0.440 neurodegeneration Do physiological concentrations of SCFAs
H2S/butyrate imbalance drives enteric alpha-synuclein pathol 0.380 parkinsons -
TFEB Activation to Restore Lysosomal Function in Parkinson's 0.380 proteomics Quantitative proteomics of the aging syn
Prevotellaceae Metabolite Depletion as Alpha-Synuclein Aggre 0.000 - Does reduced Prevotellaceae abundance ca

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (5)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Inhibition of autophagy in microglia and macrophages exacerbates innate immune r [PMID:36652438] Hegdekar N, Sarkar C, Bustos S, Ritzel R Autophagy 2023 0
Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's [PMID:37029500] Yan YQ, Zheng R, Liu Y, Ruan Y, Lin ZH, Aging cell 2023 0
Microglial NLRP3 inflammasome activates neurotoxic astrocytes in depression-like [PMID:36288697] Li S, Fang Y, Zhang Y, Song M, Zhang X, Cell reports 2022 0
Biomarker of Neuroinflammation in Parkinson's Disease. [PMID:35456966] Liu TW, Chen CM, Chang KH Int J Mol Sci 2022 0
NLRP3 inflammasome activation drives tau pathology. [PMID:31748742] ["Ising C", "Venegas C", "Zhang S", "Sch Nature 2019 0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning ALPHA_SYN in their description or question text

m6A Hypermethylation of SNCA mRNA Stabilises Alpha-Synuclein Transcript and Prom

Score: 0.662 · parkinson · 2026-04-27

N6-methyladenosine (m6A) hypermethylation of SNCA mRNA in substantia nigra dopaminergic neurons stabilises the transcrip

Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-fi

Score: 0.650 · neurodegeneration · 2026-04-24

Low-micromolar systemic SCFA exposure is unlikely to directly drive substantia nigra alpha-synuclein clearance, but colo

m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetic

Score: 0.626 · neurodegeneration · 2026-04-28

m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics should produce a measurable proximal p

H7: Enteric Nervous System Alpha-Synuclein Propagation Blocker via Gut Barrier R

Score: 0.620 · neurodegeneration · 2026-04-15

## Mechanistic Overview H7: Enteric Nervous System Alpha-Synuclein Propagation Blocker via Gut Barrier Restoration start

Cell-state stratification is required to resolve m6A RNA Modification and Alpha-

Score: 0.612 · neurodegeneration · 2026-04-28

The question is likely underpowered or misleading unless analyses preserve the key strata: m6A, RNA, N6-, alpha-synuclei

Perturbation-first validation should precede therapeutic claims for m6A RNA Modi

Score: 0.608 · neurodegeneration · 2026-04-28

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro

CSF ApoE- and clusterin-rich lipoprotein particles stabilize disease-relevant al

Score: 0.606 · neurodegeneration · 2026-04-25

Specific lipoprotein particles bind fibril surfaces and preserve polymorph architecture and seeding fidelity outside the

Ganglioside-rich extracellular vesicles preserve alpha-synuclein fibril conforma

Score: 0.582 · neurodegeneration · 2026-04-25

Membrane-derived cofactors in extracellular vesicles maintain polymorph fidelity and templating competence.

Neuronal Subtype-Specific Alpha-Synuclein Expression Normalization

Score: 0.571 · neurodegeneration · 2026-04-04

## Mechanistic Overview Neuronal Subtype-Specific Alpha-Synuclein Expression Normalization starts from the claim that mo

Direct neuronal HDAC inhibition is unlikely to mediate therapeutic alpha-synucle

Score: 0.560 · neurodegeneration · 2026-04-24

The classic butyrate neuroprotection narrative likely depends on pharmacologic exposure sufficient for HDAC inhibition,

Physiological SCFAs may worsen alpha-synuclein pathology through FFAR2/GPR43-NLR

Score: 0.550 · neurodegeneration · 2026-04-24

A key liability hypothesis is that low-range SCFA signaling can be receptor-biased toward inflammasome activation in sus

Glucosylceramide accumulation nucleates alpha-synuclein aggregation via lipid ra

Score: 0.525 · parkinsons · 2026-04-26

We propose that GBA deficiency-driven accumulation of glucosylceramide (GlcCer) in lysosomal membranes creates ordered l

Sulfated glycans and metal-binding CSF proteins brace alpha-synuclein fibril pol

Score: 0.489 · neurodegeneration · 2026-04-25

Electrostatic bridging by glycans and low-abundance proteins preserves disease-relevant fibril architecture.